## Cardioprotection for Anti-HER2 Therapy: Consideration Mildly Reduced Left Ventricular Ejection Fraction

Current Oncology Reports 24, 1063-1070 DOI: 10.1007/s11912-022-01234-y

**Citation Report** 

#	Article	IF	CITATIONS
1	Cardio-oncology: Implications for Clinical Practice for Women. Current Cardiology Reports, 2022, 24, 1685-1698.	1.3	1
2	Empagliflozin attenuates trastuzumab-induced cardiotoxicity through suppression of DNA damage and ferroptosis. Life Sciences, 2023, 312, 121207.	2.0	22